Showing results (481-490 of 1,043) with videos related to

Sort By:
Pageof 105
Gut|November 16, 2001
Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapsesW Kruis, S Schreiber, D Theuer, et al.
AJR. American Journal of Roentgenology|May 1, 1992
Occlusion and narrowing of the pharyngeal airway in obstructive sleep apnea: evaluation by ultrafast spoiled GRASS MR imagingF G Shellock, C J Schatz, P Julien, et al.
Haematologica|June 4, 2008
Chronic preclinical safety evaluation of Hematide, a pegylated peptidic erythropoiesis stimulating agent in monkeysKathryn W Woodburn, Susan D Wilson, Kei-Lai Fong, et al.
The American Journal of Pathology|May 4, 2000
Genetic and epigenetic changes in human epithelial cells immortalized by telomeraseD G Farwell, K A Shera, J I Koop, et al.
Sleep|November 26, 2009
The effect of posture on Cheyne-Stokes respirations and hemodynamics in patients with heart failureBruce A G Soll, Khung Keong Yeo, James W Davis, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 6, 1998
Asymmetric predominantly ipsilateral blepharospasm and contralateral parkinsonism in an elderly patient with a right mesencephalic cystC Singer, N J Schatz, B Bowen, et al.
Plos One|September 12, 2019
Fe limitation decreases transcriptional regulation over the diel cycle in the model diatom Thalassiosira pseudonanaJohanna A L Goldman, Megan J Schatz, Chris T Berthiaume, et al.
Circulation|November 24, 1998
Orthostatic hypotension predicts mortality in elderly men: the Honolulu Heart ProgramK H Masaki, I J Schatz, C M Burchfiel, et al.
Drug and Chemical Toxicology|March 12, 2008
Preclinical safety and pharmacology of Hematide, a peptidic erythropoiesis stimulating agent (ESA), in rats and monkeysKathryn W Woodburn, Peter J Schatz, Kei-Lai Fong, et al.
Archives of Neurology|August 1, 1982
Visual loss in pseudotumor cerebri. Follow-up of 57 patients from five to 41 years and a profile of 14 patients with permanent severe visual lossJ J Corbett, P J Savino, H S Thompson, et al.
Pageof 105